Grants per year
Personal profile
Research Interests
Dr. Ma' clinical and research interests are focused on chronic lymphoid malignancies,including chronic lymphocytic leukemia and non-Hodgkin lymphoma. Dr. Ma directs the clinical and translational research initiatives in chronic lymphocytic leukemia (CLL) to develop and study novel treatment agents for the treatment of CLL. Her translational investigations have included novel biologic agents, mechanisms of drug resistance and immunotherapy. Dr. Ma is the Principal Investigator for a number of investigator-initiated and industry-sponsored clinical trials studying new exciting treatments agents for CLL and lymphoma. She collaborates with investigators at Northwestern University, other US institutions and international institutions in developing novel therapeutic approaches in hematologic malignancies.
Certifications and Licenses
| Medical Oncology | |
| Hematology | |
| Internal Medicine |
Training Experience
| 2005 | Residency, Resurrection Hospitals |
| 2008 | Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital) |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, Northwestern University
… → 2000
MD, Beijing Medical University
… → 1994
Research interests
- Biologic Therapies
- Blood Cancer (leukemia and lymphomas)
- Chronic Lymphocytic Leukemia
- Hematology
- Non-Hodgkin's Lymphoma
- Oncology
Fingerprint
Dive into the research topics where Shuo Ma is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Roy, I., Smilnak, G., Burkart, M., Hamilton, E., Thorp, K., Miyata, S., Ma, S., Pro, B., Winter, J., Gordon, L. & Karmali, R., Apr 2022, In: British Journal of Haematology. 197, 1, p. 71-75 5 p.Research output: Contribution to journal › Article › peer-review
-
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines
Wierda, W. G., Brown, J., Abramson, J. S., Awan, F., Bilgrami, S. F., Bociek, G., Brander, D., Chanan-Khan, A. A., Coutre, S. E., Davis, R. S., Eradat, H., Fletcher, C. D., Gaballa, S., Ghobadi, A., Saad Hamid, M., Hernandez-Ilizaliturri, F., Hill, B., Kaesberg, P., Kamdar, M., Kaplan, L. D., & 14 others, Jun 2022, In: JNCCN Journal of the National Comprehensive Cancer Network. 20, 6, p. 622-634 13 p.Research output: Contribution to journal › Article › peer-review
Open Access -
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
Pearse, W. B., Petrich, A. M., Gordon, L. I., Karmali, R., Winter, J. N., Ma, S., Kaplan, J. B., Behdad, A., Klein, A., Jovanovic, B., Helenowski, I., Smith, S. M., Evens, A. M. & Pro, B., 2021, In: Leukemia and Lymphoma. 62, 14, p. 3493-3500 8 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Roeker, L. E., Eyre, T. A., Thompson, M. C., Lamanna, N., Coltoff, A. R., Davids, M. S., Baker, P. O., Leslie, L., Rogers, K. A., Allan, J. N., Cordoba, R., Lopez-Garcia, A., Antic, D., Pagel, J. M., Martinez-Calle, N., García-Marco, J. A., Hernández-Rivas, J. Á., Miras, F., Coombs, C. C., Österborg, A., & 32 others, Nov 4 2021, In: Blood. 138, 18, p. 1768-1773 6 p.Research output: Contribution to journal › Article › peer-review
Open Access21 Scopus citations -
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy
Ma, S., Seymour, J. F., Brander, D. M., Kipps, T. J., Choi, M. Y., Anderson, M. A., Humphrey, K., Al Masud, A., Pesko, J., Nandam, R., Salem, A. H., Chyla, B., Arzt, J., Jacobson, A., Kim, S. Y. & Roberts, A. W., Sep 9 2021, In: Blood. 138, 10, p. 836-846 11 p.Research output: Contribution to journal › Article › peer-review
Open Access13 Scopus citations